Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage

Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage

To investigate the neuroprotective effect of brimonidine after retinal ischemia damage on mouse eye. Glaucoma is an optic neuropathy characterized by retinal ganglion cells (RGCs) death, irreversible peripheral and central visual field loss, and high intraocular pressure. Ischemia reperfusion (I/R)...

Full description

Bibliographic Details
Main Authors:	Federica Conti, Giovanni Luca Romano, Chiara Maria Eandi, Mario Damiano Toro, Robert Rejdak, Giulia Di Benedetto, Francesca Lazzara, Renato Bernardini, Filippo Drago, Giuseppina Cantarella, Claudio Bucolo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-07-01
Series:	Frontiers in Pharmacology
Subjects:	neuroprotection retinal ganglion cells ischemia-reperfusion brimonidine PERG
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.705405/full

Similar Items

Neuroprotective properties of Brimonidine
by: Т. N. Mikhailova
Published: (2019-11-01)

Brimonidine-associated uveitis – a descriptive case series
by: Susanne Hopf, et al.
Published: (2020-12-01)

Intravitreal brimonidine inhibits form-deprivation myopia in guinea pigs
by: Yifang Yang, et al.
Published: (2021-07-01)

Efficacy of three different formulations of brimonidine for control of intraocular pressure in primary open-angle glaucoma: A 6-week randomized trial
by: Anubha Bhatti, et al.
Published: (2018-01-01)

Effect of brimonidine tartrate on basophil activation in glaucoma patients
by: Eldar Rosenfeld, et al.
Published: (2020-03-01)

Brinzolamide/Brimonidine Fixed Combination: Simplifying Glaucoma Treatment Regimens
by: Reza Moosavi, et al.
Published: (2018-10-01)

Neuroprotection in glaucoma
by: Azadeh Doozandeh, et al.
Published: (2016-01-01)

Topical brimonidine for pyogenic granuloma after paronychia surgery
by: Yusha Chen, MM, et al.
Published: (2021-01-01)

Comparison of Latanoprost and Brimonidine in the treatment of open angle glaucoma
by: Man Luo, et al.
Published: (2015-07-01)

Efficacy and safety of various brimonidine formulations in the treatment of glaucoma and ocular hypertension
by: A. V. Sidorova, et al.
Published: (2021-07-01)

Pharmacodynamic approach for proving equivalence of two ophtalmic solutions containing Brimonidine Tartarate 0.2% in healthy volunteers
by: Hristova-Valcheva Ruska, et al.
Published: (2018-01-01)

Comparison between latanoprost and brimonidine efficacy and safety in Indian eyes
by: Thomas Ravi, et al.
Published: (2003-01-01)

A Topical Formulation of Melatoninergic Compounds Exerts Strong Hypotensive and Neuroprotective Effects in a Rat Model of Hypertensive Glaucoma
by: Massimo Dal Monte, et al.
Published: (2020-12-01)

A comparative study on the efficacy of brinzolamide/timolol versus brinzolamide/brimonidine fixed drug combinations in primary open-angle glaucoma
by: Sudeepthi Padala, et al.
Published: (2020-07-01)

Neuroprotection of the rat’s retinal ganglion cells against glutamate-induced toxicity
by: Kariman M.A El-Gohari, et al.
Published: (2016-01-01)

Comparative Analysis of Pupil Diameters in Light and Dark Conditions After Instillation of 0.15% Brimonidine Drops in Eyes With and Without Pseudoexfoliation Syndrome
by: Sercan Cate, et al.
Published: (2020-12-01)

The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations
by: Ruiz Simonato Alonso, et al.
Published: (2020-03-01)

Risk Factors for Retinal Ganglion Cell Distress in Glaucoma and Neuroprotective Potential Intervention
by: Stefania Vernazza, et al.
Published: (2021-07-01)

Unilateral floppy eyelid syndrome with ipsilateral intolerance to brimonidine
by: Leidiane Adriano Pereira, et al.

RE-PERG, a new paradigm for glaucoma diagnosis, in myopic eyes
by: Mavilio A, et al.
Published: (2019-07-01)

Comparison of brimonidine-timolol and dorzolamide-timolol in the management of intraocular pressure increase after phacoemulsiﬁcation
by: Adem Turk, et al.
Published: (2015-10-01)

Neuroprotective Strategies for Retinal Ganglion Cell Degeneration: Current Status and Challenges Ahead
by: Raquel Boia, et al.
Published: (2020-03-01)

Study of Intraocular Pressure following Neodynium Yttrium Aluminium Garnet Laser Capsulotomy with the Use of Brimonidine: A Descriptive Cross-sectional Study
by: Laxmi Devi Manandhar, et al.
Published: (2021-01-01)

Neuroprotection by Wld S depends on retinal ganglion cell type and age in glaucoma
by: Michael L. Risner, et al.
Published: (2021-06-01)

Effect of Solution pH on Distribution of Ophthalmically Administered Brimonidine in Posterior Ocular Tissues in Pigmented Rabbits
by: Keisuke Shinno, et al.
Published: (2019-03-01)

Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination
by: Contreras-Salinas H, et al.
Published: (2021-02-01)

The Role of Endogenous Neuroprotective Mechanisms in the Prevention of Retinal Ganglion Cells Degeneration
by: Marita Pietrucha-Dutczak, et al.
Published: (2018-11-01)

Comparison of Glaucoma-Relevant Transcriptomic Datasets Identifies Novel Drug Targets for Retinal Ganglion Cell Neuroprotection
by: Tim J. Enz, et al.
Published: (2021-08-01)

Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension
by: Wang N, et al.
Published: (2020-01-01)

Anesthetic Preconditioning as Endogenous Neuroprotection in Glaucoma
by: Tsung-Han Chou, et al.
Published: (2018-01-01)

Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study
by: Alaa Emad Eldeeb, et al.
Published: (2019-01-01)

The Effect of Brimonidine 0.1% on Disc Hemorrhage in Primary Open-Angle Glaucoma Patients
by: Nitta K, et al.
Published: (2020-01-01)

Use of Gene Therapy in Retinal Ganglion Cell Neuroprotection: Current Concepts and Future Directions
by: Jess Rhee, et al.
Published: (2021-04-01)

Ocular and Systemic Pharmacokinetics of Brimonidine and Timolol After Topical Administration in Rabbits: Comparison Between Fixed-Combination and Single Drugs
by: Gen Suzuki, et al.
Published: (2020-01-01)

Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability
by: Anderson MS, et al.
Published: (2017-07-01)

Pre- and postsynaptic effects of brimonidine on isolated rabbit iris dilator muscles
by: Tatsui S, et al.
Published: (2016-05-01)

Dendritic Branching of Retinal Ganglion Cells as a Biomarker of Glaucomatous Optic Neuropathy and Alzheimer’s Disease and a Target of Neuroprotective Therapy
by: M. V. Zueva, et al.
Published: (2021-07-01)

Current approaches and advances in neuroprotection of glaucoma
by: Qian-Qian Hu, et al.
Published: (2014-04-01)

Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs
by: Lo JS, et al.
Published: (2016-03-01)

Influence of Mesenchymal Stem Cell Transplantation in Retaining Ganglion Cell of End Stage Glaucoma Patients
by: Widya Artini
Published: (2018-09-01)